Metastatic breast cancer is complex, requiring holistic care and ongoing treatment, with varying prognosis depending on ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

Her research seeks to answer a key question: Can exercise help slow or even prevent breast cancer progression? Morris recently spoke to Technology Networks about how her lab is trying to answer this.

An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...

Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according ...

Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...

Vepdegestrant did not improve progression-free survival broadly but saw improvements in one specific patient cohort. Arvinas’ ...

Vepdegestrant improved progression-free survival in patients with estrogen receptor 1 mutations in advanced ER-positive, HER2-negative breast cancer. Among patients with estrogen receptor-positive, ...